Neuralstem licenses spinal stem cell delivery tech for research

Neuralstem's spinal cord delivery platform will get the academic treatment, as the company has licensed the stem cell technology for research at Cedars-Sinai Medical Center in Los Angeles. With Neuralstem's floating cannula device, the platform is the first of its kind to deliver stem cells directly into the gray matter of the spinal cord. The platform is currently in Phase I trials, and the FDA has already assigned it orphan status for the treatment of Lou Gehrig's disease, giving Neuralstem 7 years of exclusivity in the market. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…